Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

(2022) Wilfredo F. Garcia-Beltran et al.   CELL

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron

(2022) Jinyan Liu et al.   NATURE

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

(2022) Roos S.G. Sablerolles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Homologous and Heterologous Covid-19 Booster Vaccinations

(2022) Robert L. Atmar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

(2022) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

(2022) Xinxue Liu et al.   JOURNAL OF INFECTION

Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study

(2022) Linda-Gail Bekker et al.   LANCET

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa

(2022) Glenda Gray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge

(2022) Jennifer M. Polinski et al.   JAMA Network Open

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance

(2021) Sandrine M. Soh et al.   JOURNAL OF MICROBIOLOGY

SARS-CoV-2 Variants and Vaccines

(2021) Philip R. Krause et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19

(2021) Yu Kaku et al.   Cell Reports

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021

(2021) Shaun J. Grannis et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Covid-19 Vaccine Effectiveness in New York State

(2021) Eli S. Rosenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

(2021) Barbara A. Cohn et al.   SCIENCE

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

(2020) Rinke Bos et al.   npj Vaccines